Are E-test and Vitek2 good choices for tigecycline susceptibility testing when comparing broth microdilution for MDR and XDR Acinetobacter baumannii?

New Microbiologica

Volumn 37, Issue 4, 2014, Pages 503-508

  Grandesso, Stefano ^a   Sapino, Barbara ^a   Amici, Gianpaolo ^b   Mazzucato, Sandra ^a   Solinas, Maria ^a   Gion, Massimo ^a  

^a OSPEDALE DELL'ANGELO   (Italy)

^b San Daniele Hospital   (Italy)

Author keywords

Acinetobacter baumannii; MDR; Susceptibility testing; Tigecycline; XDR

Indexed keywords

ACINETOBACTER BAUMANNII;

ANTIINFECTIVE AGENT; MINOCYCLINE; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PROCEDURES;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE;

EID: 84908553734     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Al-Sweih N.A., Al-Hubail M.A., Rotimi V.O. (2011). Emergence of tigecycline and colistin resistance in Acinetobacter species isolated from patients in Kuwait hospitals. J. Chemoth. 23, 16-17.
2. Bland J.M., Altman D.G. (1986). Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1, 307-311.
3. Canigia L.F., Bantar C. (2009). Susceptibility testing of tigecycline against Acinetobacter spp. by disc diffusion method: withdrawing a therapeutic option by varying the Mueller-Hinton agar? J. Antimicrob. Chem. 1463-1464.
4. Eser K.O., Ergin A., Tunckanat F., Hascelik G. (2008). In vitro activity of tigecycline as a therapeutic option againts multidrug-resistant Acinetobacter spp. New Microbiol. 31, 535-542.
5. Fernandez-Mazarrasa C., Mazarrasa O., Calvo J., del Arco A., Martinez-Martinez L. (2007). High concentrations of manganese in Mueller-Hinton agar increase MICs of tigecycline determined by E-test. Abstr. 47th Int. Conf. Antimicrob. Agents Chemother. abstr. D-227:154.
6. Kulah C., Celebi G., Aktas E., Mengeloglu Z., Comert F., Ankarali H. (2009). Unexpected Tigecycline resistance among Acinetobacter baumannii isolates: high minor error rate by Etest. J. Chemoth. 21, 390-395.
7. Livermore D.M., Hill R.L.R., Thomson H., Charlett A., Turton J.F., Pike R., Patel B.C., Manuel R., Gillespie S, Balakrishnan I., Barrett S.P., Cumberland N., Twagira M, C-MRAB Study Group. (2010). Antimicrobial treatment and clinical outcome for infections with carbapenem and multiply-resistant Acinetobacter baumannii around London. Inter. J. Antimicrobial Agents. 35, 19-24.
8. Magiorakos A.-P., Srinivasan A., Carey R.B., Carmeli Y., Falagas M.E., Giske C.G., Harbarth S., Hindler J.F., Kahlmeter G., Olsson-Liljequist B., Paterson D.L., Rice L.B., Stelling J., Struelens M.J., Vatopoulos A., Weber J.T., Monnet D.L. (2012). Multidrug-resistant, extensively drug-resistant and pandrug resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18, 268-281.
9. Marchaim D., Navon-Venezia S., Schwartz D., Tarabeia J., Fefer I., Schwaber M.J., Carmeli Y. (2007). Surveillance cultures and duration of carriage of multidrug-resistant Acinetobacter baumannii. J. Clin. Microbiol. 45, 1551-1555.
10. Navon-Venezia S., Leavitt A., Carmeli Y. (2007). High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J. Antimicrob. Chemoter. 59, 772-774.
11. Nordmann P., Naas T., Poirel L. (2011). Global spread of carbapenemase-producing Enterobacteriaceae. Emerg. Infect. Dis. 17, 1791-1798.
12. Peleg A.Y., Seifert H., Paterson D.L. (2008). Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21, 538-582.
13. Pillar C.M., Draghi D.C., Dowzicky M.J., Sahm D.F. (2008). In vitro activity of tigecycline againts gram-positive and gram-negative pathogens as evaluated by broth microdiluition and Etest. J. Clin. Microbiol. 46, 2862-2867.
14. Seifert H., Stefanik D., Wisplinghoff H. (2006). Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates. J. Antimicrob. Chemoter. 58, 1099-1100.
15. Zarkotou O., Pournaras S., Altouvas G., Pitiriga V., Tziraki M., Mamali V., Themeli-Digalaki K., Tsakris A. (2012). Comparative evalutation of Tigecycline susceptibility testing methods for expanded-spectrum cephalosporin-and carbapenem-resistant Gram-negative Pathogens. J. Clin. Microbiol. 50, 3747-3750.